title: [Sickle cell anemia and transfusion safety in Bamako, Mali. Seroprevalence of HIV, HBV and HCV infections and alloimmunization belonged to Rh and Kell systems in sickle cell anemia patients].
abstract: Red cell transfusion is one of the main treatments in sickle cell disease. However there are potential risks of blood transfusions. In order to propose strategies to improve blood safety in sickle cell disease in Mali, we conducted a prospective study of 133 patients with sickle cell anemia recruited at the sickle cell disease research and control center of Bamako, November 2010 to October 2011. The study aimed to determine the prevalence of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections by serum screening and the frequency of red cell alloimmunization before and after blood transfusion. The diagnosis of sickle cell syndrome was made by HPLC, the detection of markers of viral infection was performed by ELISA, and the diagnosis of alloimmunization was conducted by the Indirect Coombs test. Prevalence of viral infections observed at the time of enrolment of patients in the study was 1%, 3% and 1% respectively for HIV, HBV and HCV. Three cases of seroconversion after blood transfusion were detected, including one for HIV, one for HBV and one another for HCV in sickle cell anemia patients. All these patients had received blood from occasional donors. The red cell alloimmunization was observed in 4.4% of patients. All antibodies belonged to Rh system only. Blood transfusion safety in sickle cell anemia patients in Mali should be improved by the introduction of at least the technique for detecting the viral genome in the panel of screening tests and a policy of transfusions of blood units only from regular blood donors.
authors.affiliation: Centre national de transfusion sanguine, BP : E-344, Bamako, Mali. Electronic address: amadoubdiarra@yahoo.fr.
authors.forename: A B
authors.initials: AB
authors.lastname: Diarra
authors.forename: A
authors.initials: A
authors.lastname: Guindo
authors.forename: B
authors.initials: B
authors.lastname: Kouriba
authors.forename: A
authors.initials: A
authors.lastname: Dorie
authors.forename: D T
authors.initials: DT
authors.lastname: Diabaté
authors.forename: S I
authors.initials: SI
authors.lastname: Diawara
authors.forename: B
authors.initials: B
authors.lastname: Fané
authors.forename: B A
authors.initials: BA
authors.lastname: Touré
authors.forename: A
authors.initials: A
authors.lastname: Traoré
authors.forename: B
authors.initials: B
authors.lastname: Gulbis
authors.forename: D A
authors.initials: DA
authors.lastname: Diallo
mesh_terms: D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000453:epidemiology* / Q000628:therapy; D001787:Blood Group Incompatibility / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D058731:Blood Safety; D017848:Blood-Borne Pathogens; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D003298:Coombs Test; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D005260:Female; D015658:HIV Infections / Q000453:epidemiology* / Q000635:transmission; D015528:HIV Seroprevalence; D006509:Hepatitis B / Q000453:epidemiology* / Q000635:transmission; D006526:Hepatitis C / Q000453:epidemiology* / Q000635:transmission; D006801:Humans; D007114:Immunization; D007223:Infant; D007518:Isoantibodies / Q000096:biosynthesis; D007626:Kell Blood-Group System; D008297:Male; D008302:Mali; D008403:Mass Screening; D008875:Middle Aged; D011446:Prospective Studies; D012204:Rh-Hr Blood-Group System; D016036:Seroepidemiologic Studies; D065227:Transfusion Reaction; D014766:Viremia / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission*
chemical_list: D007518:Isoantibodies; D007626:Kell Blood-Group System; D012204:Rh-Hr Blood-Group System
keywords: Allo-immunisation; Drépanocytose; Infection virale; Mali; Red cell alloimmunization; Sickle cell disease; Viral infection